Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Conclusions/interpretationThere remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.
Source: Diabetologia - Category: Endocrinology Source Type: research
More News: Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Type 2 | Diets | Eating Disorders & Weight Management | Electronic Health Records (EHR) | Endocrinology | Fortamet | Heart | Heart Attack | Heart Disease | Ischemic Stroke | Metformin | Nutrition | Obesity | Peripheral Vascular Disease (PVD) | Statistics | Stroke | Study